‌ 

Being non-compliant in even a small detail of a regulation can result in the need to perform a recall. For international companies, the task of being compliant is even greater due to the need to be compliant with the regulatory bodies of multiple different markets. Each of the regulatory bodies, the FDA for example[1], has the legal authority to initiate a recall which can cause irreparable damage to a company. Often, a company will initiate a recall themselves, known as a voluntary recall[2], when they detect an issue. A voluntary recall will hopefully allow the company to mitigate the damage.

Recalls can have a drastic impact on not only the company’s financials but their reputation as well. A recall does not have to be a disastrous situation for a company. Unfortunately, having a rudimentary plan is not enough, and having no plan can lead to a worst-case scenario. Proper planning can allow a company to come out of a recall virtually unscathed, a smooth, quick, and efficient recall may even help a company’s reputation.

Integrating recall planning into already established systems will help to avoid disaster. With a proper quality management system already in place integrating the recall plan is not too much of a leap. The FDA outlines the necessary steps a company would need to take in the event of a recall, even going as far as to provide a template for the recall letter[3]. Using those procedures as a base for a recall plan will ensure that a company will meet all FDA compliance requirements in the event of a recall. Even with the guidance provided by the FDA, recall plans can still become complicated very quickly. Understanding all the necessary processes that often need to happen simultaneously can be challenging.

No organization wants a recall, but it is better to prepare to weather a storm rather than be blindsided. The trick is setting up a plan that will allow for all the required recall activities to take place as smoothly as possible. EMMA International can provide consultation services both before and during a recall. From developing a quality management system to assisting with regulatory submissions, EMMA can help bring your medical product from concept to commercialization. Give us a call at 248-987-4497 or email info@emmainternational.com to get in touch with our team of experts today.


[1] FDA (September 2018) What is a Medical Device Recall? Retrieved on 10/12/21 from: https://www.fda.gov/medical-devices/medical-device-recalls/what-medical-device-recall

[2] FDA (September 2020) Recalls, Corrections and Removals (Devices) Retrieved on 10/12/2021 from: https://www.fda.gov/medical-devices/postmarket-requirements-devices/recalls-corrections-and-removals-devices

[3] FDA (November 2020) Industry Guidance for Recalls Retrieved on 10/12/2021 from: https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/industry-guidance-recalls

Gabe Kadoo

Gabe Kadoo

Mr. Kadoo is a Quality Engineer at EMMA International. He has experience in statistical analysis, performance improvement, quality assurance, and value stream mapping in the clinical setting. Mr. Kadoo also has experience as a clinical researcher and medical technologist. Mr. Kadoo holds a Bachelor of Science in Biology and a Master of Public Administration with a concentration in Healthcare Administration. He is also a Six Sigma Green Belt.

More Resources

FDA’s Refusal to Accept Process

FDA’s Refusal to Accept Process

Before the submission of a 510(k) premarket notification, the purpose of which is to notify the FDA of the manufacturer’s intent to market a medical device,[i] there is a provision for acceptance review. This review serves as a method to assess whether a submission is administratively complete and includes all necessary information for FDA to determine substantial equivalence under section 513(i) of the Federal Food, Drug, and Cosmetic (FD&C) Act (21 United States Code (U.S.C.) § 360c(i)). To establish substantial equivalence under this provision, FDA must find the same intended use as the predicate device and either have the same technological characteristics as the predicate device or appropriate clinical and scientific data necessary to establish that the device is safe and effective as the predicate device. If the Authority is unable to determine substantial equivalence due to insufficient information, it may request for additional information to make that determination. Therefore, as a part of the acceptance review, the FDA staff follows the acceptance checklist[ii] to ensure that the application is administratively complete. These administrative elements are identified as RTA items and are required to be presented. The purpose of conducting the acceptance review is for the Lead Reviewer to determine whether the 510(k) submission meets the minimum threshold of acceptability and should be accepted for substantive review.[iii]
Empowering Your Workforce through Kaizen

Empowering Your Workforce through Kaizen

Last week, I touched on the idea of involving and empowering all employees in the workplace through the corrective and preventive actions process by fostering taking initiative and a problem-solving (refer to blogpost ‘The Art of Addressing Non-Conformances in Operations’). To expand on this concept a bit further, we’re going to be looking at Kaizen–a continuous improvement strategy in which employees at all levels are also empowered to solve problems towards big gains.
FDA’s draft guidelines on Remote Regulatory Assessments (RRAs)

FDA’s draft guidelines on Remote Regulatory Assessments (RRAs)

The pandemic has been a challenging time for all industries including the Food and Drug Administration (FDA). The FDA had to alter the manner in which it conducted its operations. One set of tools adopted by the FDA in response to COVID-19 was the remote regulatory assessment (RRAs).

Ready to learn more about working with us?

Pin It on Pinterest

Share This